CTOs on the Move


 
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.myriad.com
  • 320 Wakara Way
    Salt Lake City, UT USA 84108
  • Phone: 800.469.7423

Executives

Name Title Contact Details
Henry St Andre
Director of Information Security Profile
Robert Harrison
Chief Information Officer Profile
Kevin Haas
Chief Technology Officer Profile
Chris Williamson
Senior Vice President of Information Systems and Security Profile

Similar Companies

Celator Pharmaceuticals

Celator Pharmaceuticals is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glympse Bio

Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.

Immunitas Therapeutics

Immunitas Therapeutics is a single cell genomics-based drug discovery company.

Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Mid Atlantic Technology and Enviromental Research In

Mid Atlantic Technology and Enviromental Research In is a Castle Hayne, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.